Therefore, detailed studies on covalent and non-covalent inhibitors of the BTK kinase domain revealing the complementary conformational alterations in the whole structure of BTK are required to enhance the successful design and development of clinically effective drugs for implication in B-cell malignancies and autoimmune diseases. Here, BTK is linked to autoimmune disease.